← Eichor
Condition: Neurofibromatosis Type 1 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neurofibromatosis Type 1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Phase 3 · 132 location(s) · National Cancer Institute (NCI) · NCT04166409Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06147414A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/Phase 2 · 19 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05849662Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform
Phase 3 · 29 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07407803Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
NA · 1 location(s) · Massachusetts General Hospital · NCT07233408Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT03893643PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Phase 1 · 5 location(s) · Pasithea Therapeutics Corp. · NCT06961565FARD (RaDiCo Cohort) (RaDiCo-FARD)
Phase N/A · 15 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05954416HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Phase 2 · 1 location(s) · Shanghai Kechow Pharma, Inc. · NCT05331105Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Phase 2 · 14 location(s) · Healx Limited · NCT06541847Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)
Phase N/A · 9 location(s) · AstraZeneca · NCT07221331Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neu
NA · 1 location(s) · Centre Leon Berard · NCT05199376Natural History Study of Patients With Neurofibromatosis Type 2
Phase N/A · 1 location(s) · National Institute of Neurological Disorders and Stroke (NIN · NCT00598351Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Phase 1 · 1 location(s) · Johns Hopkins University · NCT07102394Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04085159Real-World Treatment Study of Koselugo (Selumetinib)
Phase N/A · 12 location(s) · AstraZeneca · NCT06360406Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractor
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT02390752Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Phase N/A · 3 location(s) · Universidad Nacional Autonoma de Mexico · NCT06523582MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Phase 2 · 6 location(s) · Scott R. Plotkin, MD, PhD · NCT04374305Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Phase 1/Phase 2 · 2 location(s) · AeRang Kim · NCT06735820Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and F
NA · 1 location(s) · National Cancer Institute (NCI) · NCT05361811Glioma Developmental and HyperActive Ras Tumor (DHART) Board
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05489783Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06222203Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
Phase 1/Phase 2 · 1 location(s) · Johns Hopkins University · NCT06159166Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06880991GROWing Up With Rare GENEtic Syndromes
Phase N/A · 1 location(s) · dr. Laura C. G. de Graaff-Herder · NCT04463316Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and
Phase N/A · 6 location(s) · National Cancer Institute (NCI) · NCT02544022
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.